An interesting discussion about probiotics is underway on our hometown newspaper’s website. See The New York Times blog “Well”:
We were interested to read the first comment in the queue, from an M.D. who discusses the problem of the viability of probiotic species (many don’t survive the stomach’s acidity to reach the intestines), and identifies some of the successful supplement designs, such as Florastor, that overcome this problem and have a demonstrated effectiveness. (In the case of Florastor aka Saccharomyces boulardii, the supplement has shown the capacity to decrease the incidence of a relapse in clostridium difficile colitis. It also has some other documented therapeutic successes.)
For more on Florastor, see the NYBC entry:
See also additional entries under Saccharomyces boulardii on this blog for applications and dosage recommendations.